Coloplast A Stock Alpha and Beta Analysis
| CLPBY Stock | USD 6.91 -0.20 -2.81% |
Use this module to evaluate Coloplast A's risk-adjusted performance through alpha and beta metrics. By analyzing Coloplast's alpha, you can determine whether Coloplast is generating returns above and beyond what its market sensitivity explains. Key technical indicators related to Coloplast's market risk premium analysis include: the following set:
Beta 0.42 | Alpha -0.31 | Risk 1.79 | Sharpe Ratio -0.19 | Expected Return -0.34 |
Alpha measures how much an investment outperforms or underperforms its benchmark after adjusting for risk. Beta measures sensitivity to market movements. Together they reveal whether an asset's returns are the result of skill, market exposure, or simply luck.
Coloplast |
Coloplast Market Premiums
Reviewing market premium on Coloplast A is useful because it places the security inside a risk-and-reward framework rather than evaluating return in isolation. The practical objective is to understand whether the position is adding rewarded risk, unrewarded volatility, or a mix of both inside the broader portfolio.| α | -0.3055 | β | 0.42 |
Coloplast expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Coloplast's Buy-and-hold return. Our buy-and-hold chart shows how Coloplast performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Coloplast Market Price Analysis
Studying market price indicators for Coloplast A can help investors understand whether current moves are reinforcing the thesis or signaling a weaker trading setup. Current market capitalization is about 24.94 Billion, enterprise value is near 28.84 Billion, and annual revenue is around 22.58 Billion. Used well, these indicators can help traders refine entry and exit timing instead of reacting only to headline moves.
Coloplast Return and Market Media
The median price of Coloplast for the period between Thu, Dec 11, 2025 and Wed, Mar 11, 2026 is 8.49 with a coefficient of variation of 6.7. The daily time series for the period is distributed with a sample standard deviation of 0.55, arithmetic mean of 8.27, and mean deviation of 0.49. The Stock did not receive any noticeable media coverage during the period. Price Growth (%) |
| Timeline |
About Coloplast Performance Analysis
Coloplast performance is measured on a risk-adjusted basis against benchmarks. Downside profile remains relatively contained. Coloplast shows ROE of 75.07%, ROA of 17.14%.
Unless otherwise specified, financial data for Coloplast A is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Updates may occur throughout the day.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Coloplast in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Coloplast's short interest history, or implied volatility extrapolated from Coloplast options trading.
Build Portfolio with Coloplast
Optimization tools can help investors judge whether capital allocated to Coloplast A is being used efficiently relative to other opportunities in the same equity universe. This is most useful when investors want to improve risk-adjusted return instead of simply owning more ideas at once.
Build Diversified Portfolios
Align your risk with return expectations
More Resources for Coloplast Pink Sheet Analysis
Other Information on Investing in Coloplast Pink Sheet
Coloplast financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare Coloplast across valuation measures in a consistent way.